Cancers 2014, 6(1), 526-544; doi:10.3390/cancers6010526
Review

The Role of STAT3 in Thyroid Cancer

email, email and * email
Received: 16 December 2013; in revised form: 15 February 2014 / Accepted: 27 February 2014 / Published: 6 March 2014
(This article belongs to the Special Issue STAT3 Signalling in Cancer: Friend or Foe)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Thyroid cancer is the most common endocrine malignancy and its global incidence rates are rapidly increasing. Although the mortality of thyroid cancer is relatively low, its rate of recurrence or persistence is relatively high, contributing to incurability and morbidity of the disease. Thyroid cancer is mainly treated by surgery and radioiodine remnant ablation, which is effective only for non-metastasized primary tumors. Therefore, better understanding of the molecular targets available in this tumor is necessary. Similarly to many other tumor types, oncogenic molecular alterations in thyroid epithelium include aberrant signal transduction of the mitogen-activated protein kinase, phosphatidylinositol 3-kinase/AKT (also known as protein kinase B), NF-кB, and WNT/β-catenin pathways. However, the role of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT3) pathway, a well-known mediator of tumorigenesis in different tumor types, is relatively less understood in thyroid cancer. Intriguingly, recent studies have demonstrated that, in thyroid cancer, the JAK/STAT3 pathway may function in the context of tumor suppression rather than promoting tumorigenesis. In this review, we provide an update of STAT3 function in thyroid cancer and discuss some of the evidences that support this hypothesis.
Keywords: thyroid cancer; JAK; STAT3; interleukin 6; leukemia inhibitory factor
PDF Full-text Download PDF Full-Text [403 KB, uploaded 6 March 2014 13:50 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Sosonkina, N.; Starenki, D.; Park, J.-I. The Role of STAT3 in Thyroid Cancer. Cancers 2014, 6, 526-544.

AMA Style

Sosonkina N, Starenki D, Park J-I. The Role of STAT3 in Thyroid Cancer. Cancers. 2014; 6(1):526-544.

Chicago/Turabian Style

Sosonkina, Nadiya; Starenki, Dmytro; Park, Jong-In. 2014. "The Role of STAT3 in Thyroid Cancer." Cancers 6, no. 1: 526-544.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert